Switzerland’s biotechnology sector maintained its strong investment performance in 2021. The final tally for the year came to CHF3.33 billion (US$3.4 billion), which is almost equivalent to its record-breaking total of CHF3.4 billion for 2020.
Health care private equity investor Patient Square Capital has launched Enavate Sciences, a new portfolio company with an initial capital commitment of $300 million devoted to "enabling innovation through both capital and company-building experience," CEO Jim Boylan told BioWorld. The firm, which plans to invest in both therapeutics startups and enabling technologies, plans to raise $200 million to $300 million more in 2022.
Tubulis GmbH has added considerable momentum to its effort to build a pipeline of novel antibody-drug conjugates (ADCs) by closing a €60 million (US$63.2 million) series B round. CEO and co-founder Dominik Schumacher told BioWorld the cash would enable the Munich-based firm to generate clinical proof of concept, build a clinical pipeline and continue development of its platform technologies.
Hello Heart Inc. more than doubled its fundraising to date with a $70 million series D financing round showing heart-warming support from investors for its digital therapeutic solution. Growth equity firm Stripes led the round, which brought the heart-focused digital therapeutic company’s total raised to date to more than $138 million.
The Spanish National Research Council, CSIC, has just been awarded funding from the European Research Council to establish proof of concept for new type of flat-plate positron emission tomography scanner (PET) that can be attached to the patient’s body to accurately monitor cancer proton therapy results in real time.
As many biopharmas rethink plans to go public on less-than-welcoming U.S. markets, Hillevax Inc. forged ahead, pricing an upsized IPO April 28, offering 11.8 million shares at $17 apiece, the midpoint of its previously proposed range, for gross proceeds of about $200 million. That’s the highest amount raised in a U.S. IPO so far in 2022, which saw only nine companies go public on Nasdaq during the first quarter.
RSS
